Market closed

Gossamer Bio/$GOSS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Ticker

$GOSS
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
San Diego, United States

Employees

135
Website
www.gossamerbio.com

Gossamer Bio Metrics

BasicAdvanced
$192M
-
-$0.32
1.96
-

$192M

1.96

$1.60

$0.50

1.8M

6.739

6.531

372.909

376.138

-5.23%

-11.24%

-90.26%

1.822

3.55

3.55

-135.983

-79.77%

-54.04%

What the Analysts think about Gossamer Bio

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.

Gossamer Bio Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Gossamer Bio Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Gossamer Bio News

AllArticlesVideos
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 week ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GOSS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Gossamer Bio stock?

Gossamer Bio (GOSS) has a market cap of $192M as of January 15, 2025.

What is the P/E ratio for Gossamer Bio stock?

The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of January 15, 2025.

Does Gossamer Bio stock pay dividends?

No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Gossamer Bio dividend payment date?

Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.

What is the beta indicator for Gossamer Bio?

Gossamer Bio (GOSS) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.